SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego-based medical device company, today announced that The Wall Street Transcript has published an in-depth interview with Chief Executive Officer Jim Hitchin. The interview, in its entirety, is available on the company's website at http://www.spectrascience.com/tinymce/jscripts/tiny_mce/plugins/ajaxfilemanager/uploaded/Wall%20Street%20Transcript.pdf
Mr. Hitchin said, "Each year there are literally hundreds of thousands of cases of colorectal, cervical and esophageal cancer which, because they are not diagnosed or caught early enough, result in higher mortality rates and higher costs. Our technology enables physicians to more accurately diagnose these diseases, and to do so at an earlier stage. This is critical to reducing deaths from cancer and to reducing overall costs to the healthcare system."
SpectraScience's technology provides the healthcare community with the promise of a higher degree of objectivity and sensitivity in the cancer screening process for colon cancer and cervical cancer. It is also undergoing clinical trials for an esophageal cancer screening application.
During the interview, Mr. Hitchin also reiterated that the company is focusing all resources in sales, adding that it has a competitive advantage from a technology standpoint and that there are no direct competitors to its cancer screening platforms. He emphasized that the chance to detect cancers early, or much earlier than is currently the case, means more people are going to live longer.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.
About SpectraScience, Inc.
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.
Contact: SpectraScience, Inc. Investor Relations Jim Hitchin, Chief Executive Officer Hayden Communications (858) 847-0200 x 201 Todd Pitcher (858)-518-1387 Media Relations Gitenstein & Assadi PR Susan Assadi (800) 922-8792
|SOURCE SpectraScience, Inc.|
Copyright©2009 PR Newswire.
All rights reserved